Abstract
Partial peroxisome proliferator–activated receptor-γ (PPAR-γ) agonists are known to decrease insulin resistance. Experimental studies have shown that the angiotensin type 1 receptor blocker (ARB) telmisartan has a PPAR-γ−activating property, but there does not appear to be a class effect. To test telmisartan's clinical importance, we here investigated its effect on insulin resistance in hypertensive patients with metabolic syndrome (MetS) in comparison with another ARB, losartan. A total of 42 hypertensive MetS patients (29 female, 13 male) were included (mean age: 50±9, range: 20–70 years). NCEP-ATP III criteria were used for the diagnosis of MetS. Patients were randomized to receive either telmisartan 80 mg/day (n=21) or losartan 50 mg/day (n=21) for 8 weeks. Biochemical assessments were made at baseline and at the end of the 8 weeks. Insulin resistance was evaluated by using homeostasis model assessment of insulin resistance (HOMA-IR). Both groups had similar reductions in systolic and diastolic pressures (p>0.05). HOMA-IR did not change significantly in either group throughout the study. In the telmisartan group, the mean HOMA-IR at baseline and at the end of the study were 1.9±07 and 1.9±0.5, respectively. The figures for the losartan group were 1.8±0.6 and 1.8±0.6, corresponding. In conclusion, in contrast with the reports that telmisartan may decrease insulin resistance by an effect associated with its molecular structure, 8 weeks of telmisartan treatment in the present study had a neutral effect on insulin resistance in hypertensive MetS patients, and similar results were obtained for losartan.
Similar content being viewed by others
Article PDF
References
Reaven GM : Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
Haffner SM, Ruilope L, Dahlof B, Abadie E, Kupfer S, Zannad F : Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. J Cardiovasc Pharmacol 2006; 47: 469–475.
Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program–Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203–208.
Reaven G : The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33: 283–303.
Tuck ML : Angiotensin-receptor blocking agents and the peroxisome proliferator–activated receptor-gamma system. Curr Hypertens Rep 2005; 7: 240–243.
Barbier O, Torra IP, Duguay Y, et al: Pleiotropic actions of peroxisome proliferator–activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717–726.
Yki-Jarvinen H : Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.
Derosa G, Cicero AF, Dnagelo A, et al: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepride. Hypertens Res 2005; 28: 917–924.
Ishizaka H, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M : Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005; 28: 27–34.
Lithell HO : Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203–209.
Lindholm LH, Ibsen H, Dahlöf B, et al, LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004–1010.
Giordano M, Matsuda M, Sanders L, Canessa ML, DeFronzo RA : Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44: 665–671.
Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma–modulating activity. Hypertension 2004; 43: 993–1002.
Scheen AJ, Paquot N : PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases. Rev Med Liege 2005; 60: 89–95.
Pershadsingh HA : Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator–activated receptor-gamma. Int J Biochem Cell Biol 2006; 38: 766–781.
Chobanian AV, Bakris GL, Black HR, et al, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults : Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
Maggio CA, Pi-Sunyer FX : The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997; 20: 1744–1766.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC : Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
Pershadsingh HA, Kurtz TW : Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27: 1015.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U : Angiotensin type 1 receptor blockers induce peroxisome proliferator–activated receptor-gamma activity. Circulation 2004; 109: 2054–2057.
Takai S, Kirimura K, Denan JIN, et al: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593–600.
Bastard JP, Rabasa-Lhoret R, Maachi M, et al: What kind of simple fasting index should be used to estimate insulin sensitivity in humans? Diabetes Metab 2003; 29: 285–288.
Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H : A prospective analysis of the HOMA. The Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138–1141.
Haffner SM, Miettinen H, Stern MP : The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087–1092.
Bonora E, Targher G, Alberiche M, et al: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57–63.
Lansang MC, Williams GH, Carroll JS : Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens 2001; 14: 51–53.
Kang ES, Yun YS, Park SW, et al: Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. Metabolism 2005; 54: 206–211.
Vitale C, Giuseppe Mercuro G, et al: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 15: 4–6.
World Health Organization (1999) : Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org, WHO/NCD/NCS 99.2.
Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R : Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004, 27: 457–464.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bahadir, O., Uzunlulu, M., Oguz, A. et al. Effects of Telmisartan and Losartan on Insulin Resistance in Hypertensive Patients with Metabolic Syndrome. Hypertens Res 30, 49–53 (2007). https://doi.org/10.1291/hypres.30.49
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.49
Keywords
This article is cited by
-
Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
Hypertension Research (2013)
-
A new antihypertensive drug ameliorate insulin resistance
Acta Pharmacologica Sinica (2012)
-
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients
Hypertension Research (2011)
-
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients
Hypertension Research (2011)
-
Meta-analysis of Randomized Controlled Trials Comparing Telmisartan With Losartan in the Treatment of Patients With Hypertension
American Journal of Hypertension (2008)